Previous studies have shown that in monocytes, MDM2 can bind to p53 to inhibit the anti-tumor activity, while MDM2 can bind to p53 to inhibit the killing (Namgaladze and Brüne 2021) effect of NK cells on tumor cells (Veneziani et al. 2021). This evidence concerns the gene TP53 and neoplasm.